The Annual International PfSPZ Consortium Met in Toronto, Canada

The Annual International PfSPZ Consortium Met in Toronto, Canada on November 8th & 9th, 2025

December 10, 2025 By In News No Comments
The 2025 iPfSPZ-C meeting brought together scientists from around the world to review an extraordinary year of progress in Plasmodium falciparum sporozoite (PfSPZ) vaccine and other SPZ research. Over a day and a half, 48 scientists from 11 countries presented major scientific breakthroughs, steady advances in product development, and coordinated plans for global evaluation of Sanaria’s PfSPZ-based malaria vaccines to the in-person participants and on-line participants around the world.
Read More

SANARIA VACCINE TRIAL RESULTS DEMONSTRATE UNPRECEDENTED PROGRESS IN WORLDWIDE BATTLE AGAINST VARIANT MALARIA PARASITES

June 30, 2021 By In Press Releases No Comments
In an article published today in Nature, Sanaria’s PfSPZ-CVac (CQ) vaccine is reported as being safe and protecting 100% of six subjects against a variant malaria parasite three months after their last dose in the company’s Phase 1 safety and efficacy trial. This is the first time complete protection against a variant malaria parasite has ever been achieved that long after vaccine administration.
Read More

Optimizing immunization with Sanaria® PfSPZ-CVac malaria vaccine

June 8, 2021 By In Press Releases No Comments
Sanaria and its collaborators have had to take a step by step empirical approach to optimizing immunization with PfSPZ vaccines to achieve a safe, effective, durable, and broadly protective malaria vaccine. Two recent landmark malaria vaccine studies have moved the optimization process forward and highlighted the strong protective efficacy of Sanaria® PfSPZ-CVac in malaria-naïve adults.
Read More

Safety and Differential Antibody and T-Cell Responses to the Plasmodium falciparum Sporozoite Malaria Vaccine, PfSPZ Vaccine, by Age in Tanzanian Adults, Adolescents, Children, and Infants

June 1, 2019 By In Publications No Comments

Abstract

In 2016, there were more cases and deaths caused by malaria globally than in 2015. An effective vaccine would be an ideal additional tool for reducing malaria’s impact. Sanaria® PfSPZ Vaccine, composed of radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum (Pf) sporozoites (SPZ) has been well tolerated and safe in malaria- na ̈ıve and experienced adults in the United States and Mali and protective against controlled human malaria infection with Pf in the United States and field transmission of Pf in Mali, but had not been assessed in younger age groups. We, therefore, evaluated PfSPZ Vaccine in 93 Tanzanians aged 45 years to 6 months |

Read More

News Categories

About Sanaria

Sanaria is a Maryland-based biotechnology company developing innovative vaccines that protect against malaria. We are focused on African children, the population most urgently in need of protection.

Latest News

Behind the Scenes: Vaccine Manufacturing

Contact Us

We welcome your feedback and inquiries. Please be in touch.

Address:

Sanaria Inc.
9610 Medical Center Drive, Suite 200
Rockville, MD 20850

Phone:

+1.301.770.3222

Email:

sanaria@sanaria.com

Social: